Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Joan Kyula"'
Autor:
Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to i
Externí odkaz:
https://doaj.org/article/316204113b0e4019ac28423a26ae7cf2
Autor:
Simon Smith, Hormas Ghadially, Kevin J Harrington, Alan A Melcher, Isla Leslie, Eva Crespo-Rodriguez, Galabina Bozhanova, Emmanuel C Patin, Harriet Whittock, Martin McLaughlin, Malin Pedersen, James Harper, Pablo Nenclares, Heba Soliman, Magnus T Dillon, Lorna Grove, Davina Northcote, Holly Baldock, Gabriella Baker, Joan Kyula, Jeane Guevara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell responses. Radiation and drug
Externí odkaz:
https://doaj.org/article/352213c6f2484a688ddb7a66accbad6a
Autor:
Henry G Smith, Kunzah Jamal, Jasbani HS Dayal, Tencho Tenev, Joan Kyula‐Currie, Naomi Guppy, Patrycja Gazinska, Victoria Roulstone, Gianmaria Liccardi, Emma Davies, Ioannis Roxanis, Alan A Melcher, Andrew J Hayes, Gareth J Inman, Kevin J Harrington, Pascal Meier
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 6, Pp n/a-n/a (2020)
Abstract Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti‐tumour immunity but not every form of death can elicit an immune response. Moreov
Externí odkaz:
https://doaj.org/article/ebe09b78de1144a5ac46382d903dbfad
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL/Apo-2L) has emerged as a promising anticancer agent. However, resistance to TRAIL is likely to be a major problem, and sensitization of cancer cells to TRAIL may therefore be an importa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45bce1d67630d66ee32bc58381f1e107
https://doi.org/10.1158/0008-5472.c.6497430
https://doi.org/10.1158/0008-5472.c.6497430
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 3 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771a4e22b5494372c8e40f256dd2410f
https://doi.org/10.1158/0008-5472.22374408
https://doi.org/10.1158/0008-5472.22374408
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 4 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897cc08494e7ed1138d518d5c847436b
https://doi.org/10.1158/0008-5472.22374405
https://doi.org/10.1158/0008-5472.22374405
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 1 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e91db485c26dda29269f8dfa9d487
https://doi.org/10.1158/0008-5472.22374414
https://doi.org/10.1158/0008-5472.22374414
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 2 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d6a724a528b1ec317d1b6ac8d4e6a2
https://doi.org/10.1158/0008-5472.22374411.v1
https://doi.org/10.1158/0008-5472.22374411.v1
Autor:
Victoria Roulstone, Joan Kyula, James Wright, Lu Yu, Aida Barreiro Alonso, Miriam Melake, Jyoti Choudhary, Richard Elliott, Christopher J. Lord, David Mansfield, Nik Matthews, Ritika Chauhan, Victoria Jennings, Charleen Chan, Holly Baldock, Francesca Butera, Elizabeth Appleton, Pablo Nenclares, Malin Pederson, Shane Foo, Emmanuel C. Patin, Antonio Rullan, Tencho Tenev, Pascal Meier, Jacob Van Vloten, Richard Vile, Hardev Pandha, Alan Melcher, Martin McLaughlin, Kevin Harrington
Cytoplasmic pattern recognition receptors (PRRs) for double-stranded RNA (RIG-I/MDA5) are key mediators of anti-viral responses. PRR agonists, such as dsRNA oncolytic Reovirus type 3 Dearing (Rt3D), potently activate RNA sensors. We used an unbiased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::191db321ec85e6140c0873bbc184f878
https://doi.org/10.1101/2022.09.28.508679
https://doi.org/10.1101/2022.09.28.508679
Autor:
Joan Kyula-Currie, Andrew J. Hayes, Radhika R. Patel, Khin Thway, Katharina F. Bergerhoff, James T. Paget, Victoria Roulstone, Martin McLaughlin, Henry G. Smith, Alan Melcher, Kevin J. Harrington, Aadil A. Khan, Magnus T. Dillon, David Mansfield
Publikováno v:
Clinical Cancer Research. 25:3443-3454
Purpose: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel treatment combinations that